107, 682, 716, 761, 793, 974 Baldoni, N
J Clin Endocrinol Metab (2022) 107(2):36378
doi: 10.37765/ajmc.2025.89778
Given that cardiovascular disease is a leading cause of death in MASLD/MASH [1,2] , these parallel cardiometabolic benefits confer additional target-organ protection, further reinforcing the appeal of semaglutide in this high-risk population
En la actualidad, el agonista dual de los receptores GLP-1/GIP representa una de las reas con mayor actividad en investigacin y desarrollo dentro de la industria farmacutica, con numerosas compaas multinacionales y empresas biotecnolgicas chinas acelerando sus programas clnicos
SSRIs are commonly used to treat mental health conditions by influencing the levels of serotonin in the brain